Article Text

Download PDFPDF

Response to: ‘COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study’ by Cuceoglu et al
  1. Carlo Salvarani1,2,
  2. Gianluigi Bajocchi1,
  3. Pamela Mancuso3,
  4. Elena Galli2,
  5. Francesco Muratore1,
  6. Paolo Giorgi Rossi3
  1. 1 Unit of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy
  2. 2 University of Modena and Reggio Emilia, Modena, Italy
  3. 3 Interinstitutional Epidemiology Unit, Azienda Unita Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
  1. Correspondence to Professor Carlo Salvarani, Unit of Rheumatology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia 42100, Italy; carlo.salvarani{at}

Statistics from

We appreciated the comment from Cuceoglu et al 1 in response to our paper on the susceptibility and severity of COVID-19 in a population-based cohort of patients treated with biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).2 We did not observe patients with COVID-19 <45 years in our cohort of 1195 cases with autoimmune diseases treated with b/tsDMARDs in Reggio Emilia area. Confirming our results, the authors did not observe cases of COVID-19 in a series of 173 Turkish paediatric patients with rheumatological conditions …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles